TY - JOUR
T1 - A.S.P.E.N. position paper
T2 - Clinical role for alternative intravenous fat emulsions
AU - Vanek, Vincent W.
AU - Seidner, Douglas L.
AU - Allen, Penny
AU - Bistrian, Bruce
AU - Collier, Sharon
AU - Gura, Kathleen
AU - Miles, John M.
AU - Valentine, Christina J.
AU - Kochevar, Marty
N1 - Funding Information:
A funded grant with Baxter Healthcare, Inc.
PY - 2012/4
Y1 - 2012/4
N2 - The currently available, standard soybean oil (SO)-based intravenous fat emulsions (IVFEs) meet the needs of most parenteral nutrition (PN) patients. There are alternative oil-based fat emulsions, such as medium-chain triglycerides (MCTs), olive oils (OOs), and fish oils (FOs), that, based on extensive usage in Europe, have an equivalent safety profile to SO. These alternative IVFEs are metabolized via different pathways, which may lead to less proinflammatory effects and less immune suppression. These alternative oil-based IVFEs are not currently available in the United States. Many patients who require IVFEs are already in a compromised state. Such patients could potentially have better clinical outcomes when receiving one of the alternative IVFEs to diminish the intake of the potentially proinflammatory ω-6 fatty acid-linoleic acid-which comprises more than 50% of the fatty acid profile in SO. Further research is needed on these alternative oil-based IVFEs to identify which IVFE oils or which combination of oils may be most clinically useful for specific patient populations.
AB - The currently available, standard soybean oil (SO)-based intravenous fat emulsions (IVFEs) meet the needs of most parenteral nutrition (PN) patients. There are alternative oil-based fat emulsions, such as medium-chain triglycerides (MCTs), olive oils (OOs), and fish oils (FOs), that, based on extensive usage in Europe, have an equivalent safety profile to SO. These alternative IVFEs are metabolized via different pathways, which may lead to less proinflammatory effects and less immune suppression. These alternative oil-based IVFEs are not currently available in the United States. Many patients who require IVFEs are already in a compromised state. Such patients could potentially have better clinical outcomes when receiving one of the alternative IVFEs to diminish the intake of the potentially proinflammatory ω-6 fatty acid-linoleic acid-which comprises more than 50% of the fatty acid profile in SO. Further research is needed on these alternative oil-based IVFEs to identify which IVFE oils or which combination of oils may be most clinically useful for specific patient populations.
KW - fat emulsions
KW - fatty acids, omega-3
KW - fatty acids, omega-6
KW - lipids
KW - parenteral nutrition
KW - parenteral nutrition solutions
UR - http://www.scopus.com/inward/record.url?scp=84859372220&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859372220&partnerID=8YFLogxK
U2 - 10.1177/0884533612439896
DO - 10.1177/0884533612439896
M3 - Article
C2 - 22378798
AN - SCOPUS:84859372220
SN - 0884-5336
VL - 27
SP - 150
EP - 192
JO - Nutrition in Clinical Practice
JF - Nutrition in Clinical Practice
IS - 2
ER -